Can-Fite BioPharma Ltd. (TLV: CANF)
Israel
· Delayed Price · Currency is ILS · Price in ILA
1.900
0.00 (0.00%)
Jan 21, 2025, 5:24 PM IDT
Can-Fite BioPharma Revenue
Can-Fite BioPharma had revenue of $158.00K USD in the quarter ending June 30, 2024, a decrease of -19.39%. This brings the company's revenue in the last twelve months to $667.00K, down -15.89% year-over-year. In the year 2023, Can-Fite BioPharma had annual revenue of $743.00K, down -8.27%.
Revenue (ttm)
$667.00K
Revenue Growth
-15.89%
P/S Ratio
12.02
Revenue / Employee
$83.38K
Employees
8
Market Cap
56.88M ILS
Revenue Chart
* This company reports financials in USD.
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 743.00K | -67.00K | -8.27% |
Dec 31, 2022 | 810.00K | -43.00K | -5.04% |
Dec 31, 2021 | 853.00K | 90.00K | 11.80% |
Dec 31, 2020 | 763.00K | -1.27M | -62.45% |
Dec 31, 2019 | 2.03M | -1.79M | -46.81% |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Dec 31, 2014 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Teva Pharmaceutical Industries | 62.35B |
Danel (Adir Yeoshua) | 2.71B |
Kamada | 588.75M |
Bait Bakfar | 102.08M |
Novolog (Pharm-Up 1966) | 1.73B |
Ilex Medical | 982.96M |
BrainsWay | 143.60M |
SofWave Medical | 210.53M |
Can-Fite BioPharma News
- 22 days ago - Recognition of the American Society of Clinical Oncology (ASCO) of the Liver Protective Effect of Can-Fite's anti-Cancer Drug Namodenoson - GlobeNewsWire
- 2 months ago - 60 Degrees Pharmaceuticals and Can-Fite BioPharma Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV - Accesswire
- 2 months ago - Can-Fite Achieves Milestone with First Patient Dosing in Pancreatic Cancer Phase IIa Clinical Trial - GlobeNewsWire
- 2 months ago - Can-Fite anti-Obesity Drug Namodenoson Received Patent Allowance in Australia - GlobeNewsWire
- 3 months ago - Significant Positive Results from Osteoarthritis Clinical Study in Dogs Treated with Piclidenoson - GlobeNewsWire
- 3 months ago - Can-Fite stock rallies 17% on FDA orphan drug designation - Seeking Alpha
- 3 months ago - FDA Grants Orphan Drug Designation to Can-Fite's Namodenoson for Pancreatic Cancer - GlobeNewsWire
- 4 months ago - Can-Fite: Pancreatic Carcinoma Phase IIa Clinical Study with Namodenoson Received Regulatory Authorization from the Israeli Ministry of Health - GlobeNewsWire